Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Breast Cancer Specialty Channel

Breast Cancer
Specialty Channel

Latest News

News
Addition of Atezolizumab to Chemotherapy Did Not Improve Overall Survival Among Patients With Early Relapsing Unresectable Advanced Triple-Negative Breast Cancer
07/16/2024
Results from the phase 3 IMpassion132 study demonstrated that the addition of atezolizumab to chemotherapy did not improve overall survival among patients with early relapsing unresectable advanced or metastatic triple-negative breast cancer.
Results from the phase 3 IMpassion132 study demonstrated that the addition of atezolizumab to chemotherapy did not improve overall survival among patients with early relapsing unresectable advanced or metastatic triple-negative breast cancer.
Results from the phase 3...
07/16/2024
Oncology
News
First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
07/11/2024
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT...
07/11/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
News
Abemaciclib Plus Nonsteroidal Aromatase Inhibitor Improved Survival Outcomes Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
05/23/2024

Stephanie Holland 

Stephanie Holland 
According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...
According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...
According to final overall...
05/23/2024
Oncology
News
Datopotamab Deruxtecan Shows Promising Activity, Safety Among Heavily Pretreated Patients With HR-Positive, HER2-Negative, or Triple-Negative Breast Cancer
05/14/2024

Stephanie Holland 

Stephanie Holland 
According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...
According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or...
According to results from the...
05/14/2024
Oncology
News
Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
04/18/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive,...
According to results from the...
04/18/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
Addition of Palbociclib to Fulvestrant Did Not Improve Progression-Free Survival Among Pre-Treated Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
04/04/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...
According to results from the phase 2 PACE study, the addition of palbociclib to fulvestrant did not improve PFS among patients with HR-positive, HER2-negative metastatic breast cancer who experienced disease progression after treatment with...
According to results from the...
04/04/2024
Oncology
News
Ribociclib Added to Endocrine Therapy Improved Disease-Free Survival Among Patients With HR-Positive, HER2-Negative Early Breast Cancer
04/04/2024

Stephanie Holland

Stephanie Holland
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results from an international phase 3 trial, ribociclib plus either letrozole or anastrozole significantly improved disease-free survival among patients with HR-positive, HER2-negative early breast cancer.
According to interim results...
04/04/2024
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Quizzes

Quiz
First-Line Administration of Subtype-Based Therapy for Patients With Previously Untreated, Metastatic/Recurrent Triple-Negative Breast Cancer
02/02/2024
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the...
02/02/2024
Oncology
Quiz
Quiz: Are All CDK4/6 Inhibitors Created Equal?
12/15/2022
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor palbociclib impact overall survival in patients with ER+/HER2- breast cancer?
How did CDK4/6 inhibitor...
12/15/2022
Oncology
Quiz
Quiz: Breast Cancer Subtypes With Differing Times to Recurrence
12/15/2022
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence better for patients with ER-positive/HER2-negative breast cancer with the HER-2E biomarker compared to those without?
Was the time-to-recurrence...
12/15/2022
Oncology
Quiz
Quiz: Brain Metastasis and Breast Cancer Subtype
12/14/2022
Is there a link between brain metastasis incidence and breast cancer subtype among patients with metastatic breast cancer?
Is there a link between brain metastasis incidence and breast cancer subtype among patients with metastatic breast cancer?
Is there a link between brain...
12/14/2022
Oncology
Quiz
Quiz: PATH Regimen for ERBB2+ Breast Cancer
12/14/2022
What was the pathological complete response rate of patients with ERBB2-positive breast cancer treated with the PATH regimen?
What was the pathological complete response rate of patients with ERBB2-positive breast cancer treated with the PATH regimen?
What was the pathological...
12/14/2022
Oncology
Quiz
Quiz: Effect of Tomaxafin on Hemorrhage Risk
12/14/2022
Did treatment with tamoxifen plus a direct oral anticoagulant for breast cancer increase patient hemorrhage risk vs an aromatase inhibitor plus direct oral anticoagulant?
Did treatment with tamoxifen plus a direct oral anticoagulant for breast cancer increase patient hemorrhage risk vs an aromatase inhibitor plus direct oral anticoagulant?
Did treatment with tamoxifen...
12/14/2022
Oncology
Quiz
Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Advanced Triple-Negative Breast Cancer
11/04/2022
Did results of the the KEYNOTE-355 trial find that pembrolizumab plus chemotherapy improved overall survival vs chemotherapy alone in patients with advanced triple-negative breast cancer?
Did results of the the KEYNOTE-355 trial find that pembrolizumab plus chemotherapy improved overall survival vs chemotherapy alone in patients with advanced triple-negative breast cancer?
Did results of the the...
11/04/2022
Oncology
Quiz
Quiz: [18F]FES-PET or Biopsy to Determine ER Status of Metastatic Breast Cancer?
08/30/2022
How diagnostically accurate is 16a-[18F]fluoro-17b-estradiol positron emission tomography to assess ER status of metastatic breast cancer vs biopsy of a metastasis?
How diagnostically accurate is 16a-[18F]fluoro-17b-estradiol positron emission tomography to assess ER status of metastatic breast cancer vs biopsy of a metastasis?
How diagnostically accurate is...
08/30/2022
Oncology
Quiz
Quiz: Breast Cancer PFS With Elacestrant vs Standard Endocrine Monotherapy
08/30/2022
Which patients, if any, experienced improved progression-free survival when treated with elacestrant compared to standard of care endocrine monotherapy?
Which patients, if any, experienced improved progression-free survival when treated with elacestrant compared to standard of care endocrine monotherapy?
Which patients, if any,...
08/30/2022
Oncology
Quiz
Quiz: Does Trastuzumab Deruxtecan Show Greater Efficacy than Standard of Care in HER2-Positive BC?
04/26/2022
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab...
04/26/2022
Oncology
Quiz
Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer
08/08/2024
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?
Do you know whether maintenance...
08/08/2024
Oncology
Quiz
Recommended Dostarlimab Dose for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/08/2024
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...
Based on results from the phase...
08/08/2024
Oncology
Quiz
Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer
08/05/2024
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...
True or False: According to...
08/05/2024
Oncology
Quiz
Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer
07/15/2024
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?
According to the final analysis...
07/15/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma
07/12/2024
07/12/2024
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment
07/03/2024
07/03/2024
Oncology
Quiz
FDA Approval of Lisocabtagene Maraleucel for MCL
07/01/2024
07/01/2024
Oncology
Quiz
Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer
06/28/2024
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).
True or False: As reported in...
06/28/2024
Oncology
Quiz
Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer
06/26/2024
What adjuvant treatment would you recommend?
What adjuvant treatment would you recommend?
What adjuvant treatment would...
06/26/2024
Oncology

Advertisement

Advertisement

Advertisement

Hear From the Experts:

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement